Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...

Discover potential risks for Novo Nordisk using Charlie Munger's inversion model. Explore market share, R&D, and why this ...

Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

Sure, nobody goes around boasting, "We're Number Two!" But in certain circumstances, coming in second has its advantages.

Eli Lilly (NYSE:LLY) announced Wednesday that an executive search is underway to find an internal or external replacement for ...

Memory change is not always a part of normal aging, with more than 7 million adults living with Alzheimer’s disease in the ...

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits ...

Eli Lilly's top neuroscience executive, Anne White, is retiring after three decades with the drugmaker. Eli Lilly on Wednesday said White will remain in her post as executive vice president and ...

The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.

On May 12, Trump signed an executive order stating that U.S. consumers are being overcharged for prescription drugs and that ...

Dining under palm trees on a patio at Mar-a-Lago in December, President-elect Donald Trump reassured chief executives at ...

In vivo CAR T-cell therapies promise to revolutionize cancer treatment, enhancing access and reducing costs while addressing ...